You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

46 Results
Guidelines and Advice
Status: Current
ID: ES 15-5
Version: 3
Nov 2023
Drug
Other Name(s): Torisel ®
Jun 2024
Drug
Other Name(s): Stivarga®
Nov 2023
Drug
Other Name(s): Somatuline® Autogel®
Jun 2024
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
New Drug Funding Program
    Temsirolimus - Metastatic Renal Cell Carcinoma
Jun 2024
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Metastatic Breast Cancer
Nov 2023
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI)
Intent: Palliative
Jun 2024
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI)
Intent: Palliative
Jun 2024
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI), 
Lung, 
Neuroendocrine (Lung)
Intent: Palliative
Funding:
ODB - General Benefit
    octreotide
Jun 2024
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Nov 2023
Regimen
Cancer Type:
Sarcoma, 
Osteogenic / Bone
Intent: Adjuvant, Neoadjuvant, Palliative
Nov 2023
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI)
Intent: Palliative
Funding:
Exceptional Access Program
    SUNItinib - For patients who have progressive, unresectable, well or moderately differentiated, locally advanced or metastatic pancreatic neuroendocrine tumours (pNET), according to specific criteria
Jun 2024

Pages